EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

PD-L1 expression • EGFR mutation • ALK fusion • ROS1 fusion

carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • Enshuxing (enlonstobart)

EVM16CX01: EVM16 Injection as a Single and Combination With Tislelizumab in Solid Tumors (clinicaltrials.gov)

P1, N=78, Recruiting, Peking University | Trial completion date: Jun 2028 --> Dec 2028

2 days ago

Trial completion date

Tevimbra (tislelizumab-jsgr)

Paclitaxel plus ramucirumab and tislelizumab as switch maintenance versus continuation of chemotherapy and tislelizumab in patients with advanced HER2-negative and PD-L1 positive gastroesophageal adenocarcinoma: the ARMANI-2/ENGIC08 trial by GONO (2025-524048-36-00)

P2/3, N=172, Not yet recruiting, Gruppo Oncologico Del Nord Ovest

3 days ago

New P2/3 trial

HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)

HER-2 negative

cisplatin • paclitaxel • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • Cyramza (ramucirumab) • oxaliplatin • leucovorin calcium

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for Locally Advanced Mid-low Rectal Cancer (clinicaltrials.gov)

P=N/A, N=47, Completed, Beijing Friendship Hospital | Not yet recruiting --> Completed | N=26 --> 47 | Trial completion date: Mar 2024 --> May 2026 | Trial primary completion date: Dec 2023 --> Apr 2026

6 days ago

Trial completion • Enrollment change • Trial completion date • Trial primary completion date

Tevimbra (tislelizumab-jsgr) • Zadaxin (thymalfasin)

Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer. (clinicaltrials.gov)

P2, N=52, Not yet recruiting, Ming Liu

6 days ago

New P2 trial

PD-L1 (Programmed death ligand 1)

Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin

TITANS: A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC) (clinicaltrials.gov)

P=N/A, N=440, Recruiting, BeOne Medicines

7 days ago

New trial • HEOR • Real-world evidence

PD-L1 (Programmed death ligand 1)

Tevimbra (tislelizumab-jsgr)

TitAN: Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study (clinicaltrials.gov)

P2, N=34, Recruiting, Qilu Hospital of Shandong University | Not yet recruiting --> Recruiting

9 days ago

Enrollment open

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)

Focus V (anlotinib) • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel

PD-1 inhibitor combined with chemoradiotherapy in two cases of ovarian cancer brain metastases: a case report. (PubMed, Front Oncol)

One patient had a single brain metastasis and received comprehensive treatment including surgery, radiotherapy, chemotherapy, PD-1 inhibitor (tislelizumab), and PARP inhibitor (niraparib). The immune microenvironment characteristics of brain metastases (e.g., high PD-L1 expression, T-cell infiltration) may predict the efficacy of immunotherapy, but the prognosis for patients with multiple brain metastases remains poor. Further research is needed to explore the correlation between peripheral blood immune markers and treatment response in brain metastases.

9 days ago

Journal • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • HRD (Homologous Recombination Deficiency) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)

PD-L1 expression • PD-L1 overexpression • HRD

Tevimbra (tislelizumab-jsgr) • Zejula (niraparib)

Distinct multiplex immunofluorescence-based immune and stromal marker expression profile of subcutaneously metastatic SMARCA4-deficient undifferentiated thoracic tumor: a case report. (PubMed, Transl Lung Cancer Res)

The patient received four cycles of tislelizumab combined with albumin-bound paclitaxel and carboplatin, followed by four cycles of tislelizumab monotherapy maintenance. The distinct marker expression profile in subcutaneous metastatic lesions (high CD56, PD-1, and pan-CK expression with low CD8, CD68, and CD20 expression) reflects the unique TME of SMARCA4-UT, which may be related to its metastatic potential and immunotherapeutic response. Chemotherapy combined with immunotherapy shows promising efficacy in the treatment of SMARCA4-UT, and the mIF-based marker profile may provide a potential basis for optimizing individualized treatment strategies.

9 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • NCAM1 (Neural cell adhesion molecule 1) • CD68 (CD68 Molecule)

carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel

14d

The Application of Locoregional Therapy Combined With Systemic Therapy in the Perioperative Period of Huge Hepatocellular Carcinoma: A Retrospective Cohort Study (clinicaltrials.gov)

P=N/A, N=715, Completed, Tongji Hospital

14 days ago

New trial

Keytruda (pembrolizumab) • Avastin (bevacizumab) • Tecentriq (atezolizumab) • sorafenib • Tyvyt (sintilimab) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • AiTan (rivoceranib) • Stivarga (regorafenib) • Zepsun (donafenib)

14d

CJDQ443B12105B: Rollover study for participants who are currently being treated with and are continuing to benefit from opnurasib as a single agent or in combination with other study treatments. (2025-523537-26-00)

P1/2, N=16, Not yet recruiting, Novartis Pharma AG

14 days ago

New P1/2 trial

Erbitux (cetuximab) • Tevimbra (tislelizumab-jsgr) • batoprotafib (TNO155) • opnurasib (JDQ443)